Home › NDC Lookup › Ingredients › Celecoxib › 00591-3982-60
💊image loading
(from DailyMed)

Celecoxib 50 mg Capsule, 60-count — NDC 0591-3982-60 (Billing 00591-3982-60)

by Actavis Pharma, Inc. · 60 CAPSULE in 1 BOTTLE

This is a package of 60 capsules of Celecoxib 50 mg Capsule from Actavis Pharma, Inc., marketed since Mar 2015 and currently FDA-listed; retail pharmacies pay about $0.0914 per capsule (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00591-3982-60
🏷️ FDA NDC (as labeled) 0591-3982-60 billing pads the labeler segment with a zero
This package
Contains60-count Cost per ea$0.0914 NADAC Per package$5.48 / 60 capsules Pack sizes2 compare ↓
Also priced by: Part D plans $0.2958/unit — full pricing hub ↓
Main listing for product 0591-3982 · Also comes in: 28735 capsules 0591-3982-00
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Celecoxib (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · May 13, 2025 — Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules (AvKARE) · FDA recall D-0460-2025
Class II · May 9, 2025 — Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule (Alembic Pharmaceuticals Limited) · FDA recall D-0459-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0591-3982-60
Product NDC 0591-3982
11-digit billing NDC 00591398260
NCPDP billing unit EA — each (per item)
SPL Set ID 909300ab-8281-4b94-90c6-c124316e9faa
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2015-03-12
Dosage form CAPSULE
Substance CELECOXIB

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 66100525000110
GPI class Celecoxib
GCN Seq No 062001
GCN 97785
HICL code 018979
Ingredient (HICL) Celecoxib
HIC1 code S
Therapeutic class — broad (HIC1) Locomotor System
HIC2 code S2
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On Joints
HIC3 code S2L
Therapeutic class — specific (HIC3) Nsaids,Cyclooxygenase-2(Cox-2) Selective Inhibitor
AHFS code 28:08.04.08
AHFS class Cyclooxygenase-2 (Cox-2) Inhibitors
FDB label name CELECOXIB 50 MG CAPSULE
FDB brand name Celecoxib
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 062001
  • GCN: 97785
  • GPI-14 (Medi-Span): 66100525000110
  • HICL (First Databank): 018979
  • AHFS class code: 28:08.04.08
Why two NDCs? The FDA registers this code as 0591-3982-60 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00591-3982-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name CELECOXIB 50 MG CAPSULE Ingredient Celecoxib
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Celebrex and generic capsules are used for several types of arthritis, acute pain and painful periods. Vyscoxa liquid is for certain arthritis types. ELY...
  • For capsules, usual doses can be taken with or without food, but higher doses are taken with food. Vyscoxa suspension must be taken on an empty stomach, at least 2 hours before or...
  • The most common ones are stomach upset, indigestion, diarrhea, gas, swelling, dizziness, cold-like symptoms and rash. Call your doctor if they bother you or don't go away.
  • Get emergency help for chest pain, shortness of breath, weakness on one side, slurred speech, black or bloody stools, vomiting blood, or swelling of the face or throat. Stop it and...
📖 Read our full Celecoxib guide →
1
Nutrient depletion considerations

Celecoxib may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Celecoxib nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.091 $5.48 / 60 capsules
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.2958 $17.75 / 60 capsules
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Sep 2022 Jan 2026 Sep 2026 $0.206 $0.082
▲ Up 1% over the last 23 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00591-3982-60 You're viewing this Main listing 60 CAPSULE in 1 BOTTLE $0.0914 / ea $5.48 2015-03-12 — Active
00591-3982-00 0591-3982-00 28735 CAPSULE in 1 CONTAINER — — — — Active

You're viewing the smallest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 60-count package — 60 capsule in 1 bottle.
How does this package differ from NDC 00591-3982-00?
Both are Celecoxib 50 mg Capsule — the drug itself is identical. This page's package is the 60-count one, while NDC 00591-3982-00 is the 28735 capsules package.
What NDC number is used to bill for this package of Celecoxib 50 mg Capsule?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Celecoxib 50 mg 42806-0720-60 EPIC 60 capsules $0.088 AB Availability likely save 3%
Celecoxib 50 mgthis 00591-3982-60 Actavis 60 capsules $0.091 — Availability likely —
Celecoxib 50 mg 11788-0112-60 AiPing 60 capsules $0.091 AB Availability likely —
Celecoxib 50 mg 16714-0731-01 NorthStar 60 capsules $0.091 AB Availability likely —
Celecoxib 50 mg 27808-0295-01 Cranbury 60 capsules $0.091 AB Availability likely —
celecoxib 50 mg 33342-0155-09 Macleods 60 capsules $0.091 AB Availability likely —
Celecoxib 50 mg 65862-0907-60 Aurobindo 60 capsules $0.091 AB Availability likely —
celecoxib 50 mg 68180-0395-07 Lupin 60 capsules $0.091 AB Availability likely —
Celecoxib 50 mg 72241-0022-03 Modavar 60 capsules $0.091 AB Availability likely —
Celecoxib 50 mg 83301-0028-01 Mullan 60 capsules $0.091 AB Availability likely —
Celebrex 50 mg 58151-0082-91 Viatris 60 capsules $4.454 AB FDA listed +4774%
celecoxib 50 mg 13668-0307-01 Torrent 100 capsules — AB FDA listed —
Celecoxib 50 mg 23155-0963-06 Avet 60 capsules — AB FDA listed —
Celecoxib 50 mg 29300-0157-16 Unichem 60 capsules — — FDA listed —
Celecoxib 50 mg 42571-0142-05 Micro 500 capsules — AB FDA listed —
Celecoxib 50 mg 46708-0267-10 Alembic 100 capsules — AB FDA listed —
Celecoxib 50 mg 50228-0156-10 ScieGen 1000 capsules — AB FDA listed —
Celecoxib 50 mg 57582-0211-01 Tianjin 60 capsules — AB FDA listed —
Celecoxib 50 mg 60290-0016-01 Umedica 100 capsules — AB FDA listed —
Celecoxib 50 mg 62332-0140-08 Alembic 80 capsules — AB FDA listed —
Celecoxib 50 mg 69097-0423-02 Cipla 30 capsules — AB FDA listed —
Celecoxib 50 mg 69117-0020-01 Yiling 60 capsules — AB FDA listed —
Celecoxib 50 mg 70247-0006-06 Qingdao 60 capsules — AB FDA listed —
Celecoxib 50 mg 71209-0054-03 Cadila 60 capsules — AB FDA listed —
Celecoxib 50 mg 75834-0236-05 NIVAGEN 500 capsules — AB FDA listed —
Celecoxib 50 mg 76420-0726-01 Asclemed 1 capsule — AB FDA listed —
Celecoxib 50 mg 76420-0842-00 Asclemed 1000 capsules — AB FDA listed —
Celecoxib 50 mg 77771-0156-60 Radha 60 capsules — AB FDA listed —
Celecoxib 50 mg 85534-0066-00 HAWAII 30 capsules — AB FDA listed —
celecoxib 50 mg 85534-0059-00 HAWAII 30 capsules — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2015
On the market since
Mar 2015
📍
2026
Currently FDA-listed
11 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerActavis Pharma, Inc.
Labeler code00591
First marketedMar 2015
Product typeDrug For Further Processing
Portfolio324 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Celecoxib (matched by generic name) — the program that covers self-administered drugs. 25 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Celecoxib. CMS lists 4 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$38.36M
Claims incl. refills
1.6M
Beneficiaries
1.1M
Spend / beneficiary
$34.12
Spend / claim
$23.40
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Actavis Pharma, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Actavis Pharma, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 28735 capsules (00591-3982-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Actavis Pharma, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00591-3955-50 · Actavis 00591-3983-01 · Actavis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.